Although it has been possible to obtain a prescription for cannabis medicines in Switzerland for a number of years, it is not uncommon for patients to incur considerably higher costs than if they were to obtain cannabis products on the black market. Prof. Dr. med. Reto Auer, Bern Institute of Family Medicine, explained the nature of this dilemma in his presentation.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Psychedelics and related drug classes
Ritual, party or new therapy? Psychedelics and more: clinically illuminated
- Acute sinusitis: real-world study on first-line therapy
Focusing on a rational therapeutic approach beyond antibiotics
- DOAK optimization, ABC pathway and lessons learned from the FXI/XIa pipeline
Stroke prevention for atrial fibrillation 2025
- From symptom to diagnosis
Abdominal pain – Hernias
- "Survey of Health, Ageing and Retirement in Europe" (SHARE)
Analysis of polypharmacy in ≥65-year-olds
- New perspectives for clinics and research
Ageing, cellular senescence and Parkinson’s disease
- From early intervention to individualization
The new guidelines at a glance
- Artificial intelligence
 
						
						 
					 
			 
						 
						 
																	 
																	 
																	 
																	 
																	 
																	 
																	